4TEEN4 Pharmaceuticals

Executive Summary

4TEEN4 Pharmaceuticals is a German biotech company dedicated to developing therapies for cardiogenic shock, a life-threatening condition with mortality rates exceeding 70% in intensive care units. The company’s lead asset targets Dipeptidyl Peptidase 3 (DPP3), a key enzyme implicated in the pathophysiology of cardiogenic shock, which affects up to 200,000 patients annually in the U.S. Despite advances in care, 30-day mortality remains between 50-70%, underscoring a critical unmet need. 4TEEN4’s approach aims to neutralize DPP3, thereby restoring cardiovascular function and improving survival outcomes. The company is currently advancing its lead candidate through Phase 2/3 clinical trials, positioning it as a potential first-in-class therapy for cardiogenic shock. With a strong scientific rationale and a focus on a high-mortality indication, 4TEEN4 represents a compelling opportunity in the cardiovascular space. Upcoming milestones include top-line data from the ongoing Phase 2/3 study, which could de-risk the program and attract partnership interest. Given the severe unmet need and the lack of approved targeted therapies, successful development could offer significant clinical and commercial value.

Upcoming Catalysts (preview)

• Q4 2026Phase 2/3 Top-Line Data Readout50% success
• Q1 2027End-of-Phase 2/3 Meeting with FDA70% success
• TBDPotential Strategic Partnership or Licensing Deal30% success